The GTPBP10 Knockout Jurkat Polyclonal Cells product comprises a population of CRISPR/Cas9-edited Jurkat T lymphoblasts carrying a targeted disruption of the GTPBP10 gene. This polyclonal knockout pool, generated through non-homologous end joining-mediated gene disruption, provides a heterogeneous loss-of-function model suitable for studying mitochondrial biology in a human T-cell leukemia background. The use of a polyclonal population captures diverse genetic lesions, enabling robust functional assessments while minimizing clonal artifacts. Researchers can employ this model to dissect GTPBP10-dependent processes without the constraints of a single clonal isolate, making it a versatile tool for mechanistic and translational studies.
Jurkat cells are an immortalized human T-lymphoblast line derived from an acute T-cell leukemia patient. Widely employed as a model for T-cell antigen receptor signaling, apoptosis, and leukemogenesis, these suspension-adapted cells exhibit rapid proliferation and well-characterized signal transduction networks. Their leukemic origin endows them with metabolic flexibility and oncogenic signaling dependencies, including constitutive activation of the PI3K/AKT/mTOR axis, which provides a relevant context for examining mitochondrial function in malignant T cells. This background makes Jurkat cells particularly suited for probing the intersection of mitochondrial homeostasis and cancer cell viability.
GTPBP10 encodes an evolutionarily conserved mitochondrial GTPase essential for the biogenesis of the large subunit of the mitochondrial ribosome. The protein forms complexes with multiple mitochondrial ribosomal large subunit (MRPL) proteins and the assembly factor C7orf30, and requires GTP binding for proper function. It acts downstream of the mitochondrial import receptor TOM20 and is regulated by mitochondrial stress signals and mTOR kinase activity, linking nutrient sensing to mitochondrial gene expression. Disruption of GTPBP10 impairs the assembly of the mt-LSU, thereby reducing translation of mitochondrial-encoded polypeptides such as MT-CO1, which are core subunits of electron transport chain complexes. Consequently, knockout cells exhibit diminished oxidative phosphorylation and altered mitochondrial proteostasis, triggering the mitochondrial unfolded protein response (UPRmt).
In the Jurkat T-cell leukemia model, GTPBP10 deficiency creates a state of mitochondrial dysfunction that intersects with oncogenic signaling. Impaired mt-LSU assembly leads to suppressed mitochondrial translation, reducing electron transport chain activity and forcing a metabolic shift that may influence proliferation and survival. Given the reliance of leukemic T cells on mTOR-driven anabolic processes, the loss of GTPBP10 can modulate sensitivity to metabolic stressors and therapeutic agents. This model thus provides a unique platform to investigate how mitochondrial ribosome dysfunction impacts T-cell malignancy, metabolic adaptation, and apoptotic signaling, with potential implications for understanding mitochondrial disorders and metabolic syndromes.
Typical research applications include mitochondrial translation assays using puromycin labeling to measure de novo synthesis of mtDNA-encoded proteins, western blotting for representative electron transport chain subunits, and RT-qPCR for mitochondrial transcripts. The knockout cells are also amenable to metabolic flux analyses with Seahorse platforms, flow cytometric assessment of mitochondrial mass and membrane potential, cell viability screens, and apoptosis detection via annexin V staining. These modalities facilitate drug sensitivity profiling and studies of redox homeostasis in a T-cell context. For further technical details or customized experimental support, please contact Ascent Research.
